Petlife Pharmaceuticals, Inc.
PTLF
$0.0001
$0.000.00%
| 02/28/2018 | 11/30/2017 | 08/31/2017 | 05/31/2017 | 02/28/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -85.44% | -98.99% | -56.51% | 361.29% | 861.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.44% | -98.99% | -55.97% | 361.29% | 861.61% |
| Operating Income | 85.44% | 98.99% | 55.97% | -361.29% | -861.61% |
| Income Before Tax | 67.57% | 97.56% | 39.82% | -557.26% | -909.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.57% | 97.56% | 39.82% | -557.26% | -909.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.57% | 97.56% | 39.82% | -557.26% | -909.04% |
| EBIT | 85.44% | 98.99% | 55.97% | -361.29% | -861.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 80.68% | 99.29% | 95.84% | 20.25% | -72.51% |
| Normalized Basic EPS | 85.95% | 99.29% | 96.38% | 40.20% | -72.90% |
| EPS Diluted | 80.68% | 99.29% | 95.84% | 20.25% | -72.51% |
| Normalized Diluted EPS | 85.95% | 99.29% | 96.38% | 40.20% | -72.90% |
| Average Basic Shares Outstanding | 67.00% | 241.29% | 1,349.16% | 720.55% | 484.99% |
| Average Diluted Shares Outstanding | 67.00% | 241.29% | 1,349.16% | 720.55% | 484.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
